This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial


Aarsland, Dag, Ballard, Clive, Walker, Zuzana, Bostrom, Fredrik, Alves, Guido, Kossakowski, Katja, Leroi, Iracema, Pozo-Rodriguez, Francisco, Minthon, Lennart, Londos, Elisabet


The Lancet. Neurology, Volume: 8, No.: 7, Pages.: 613-618

Year of Publication



Background: Dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) are common forms of dementia that substantially affect quality of life. Currently, the only treatment licensed for PDD is rivastigmine, and there are no licensed treatments for DLB. We aimed to test the safety and efficacy of the N-methyl D-aspartate (NMDA) receptor antagonist memantine in patients with PDD or DLB.; Methods: We did a parallel-group, 24-week, randomised controlled study of memantine (20 mg per day) versus placebo at four psychiatric and neurological outpatient clinics in Norway, Sweden, and the UK during 2005-08. Patients were included if they fulfilled the UK Parkinson’s Disease Society Brain Bank clinical diagnostic criteria for Parkinson’s disease (PD) and developed dementia according to the Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM IV) criteria at least 1 year after the onset of motor symptoms (PDD) or met the revised consensus operationalised criteria for DLB. Patients were assigned to a computer-generated randomisation list. All physicians who had contact with patients were masked to treatment allocation. The primary outcome measure was clinical global impression of change (CGIC), which ranged from 1 to 7 points, and a low score means a better outcome. Analysis was by intention to treat based on the last observation carried forward. This trial is registered, number ISRCTN89624516.; Findings: 72 patients with PDD or DLB were randomly assigned and started treatment: 34 with memantine and 38 with placebo. 56 (78%) completed the study. All withdrawals were owing to adverse events, but the proportion of withdrawals was similar in both groups. At week 24 the patients in the memantine group had better CGIC scores than those taking placebo (mean difference 0.7, 95% CI 0.04-1.39; p=0.03). With the exception of improved speed on attentional tasks in the memantine group (a quick test of cognition [AQT] form: difference 12.4, 95% CI 6.0-30.9; p=0.004), there were no significant differences between the groups in secondary outcome measures.; Interpretation: Patients with DLB or PDD might benefit from treatment with memantine, which was well tolerated. Large-scale studies are now required to confirm our preliminary findings.; Funding: The Western Norway Regional Health Authority; H Lundbeck A/S.;

Bibtex Citation

@article{Aarsland_2009, doi = {10.1016/s1474-4422(09)70146-2}, url = {}, year = 2009, month = {jul}, publisher = {Elsevier {BV}}, volume = {8}, number = {7}, pages = {613--618}, author = {Dag Aarsland and Clive Ballard and Zuzana Walker and Fredrik Bostrom and Guido Alves and Katja Kossakowski and Iracema Leroi and Francisco Pozo-Rodriguez and Lennart Minthon and Elisabet Londos}, title = {Memantine in patients with Parkinson{textquotesingle}s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial}, journal = {The Lancet Neurology} }


administration & dosage, adverse effects, aged, aged, 80 and over, brain, cognition, cognition disorders, double-blind method, drug effects, drug therapy, excitatory amino acid antagonists, female, glutamic acid, humans, lewy body disease, male, memantine, metabolism, methods, neuropsychological tests, outcome assessment (health care), parkinson disease, patient selection, physiology, physiopathology, placebo effect, placebos, psychomotor performance, reaction time, treatment outcome

Countries of Study

Norway, Sweden, UK

Types of Dementia

Lewy-Body, Parkinson’s Dementia

Types of Study

Randomised Controlled Trial

Type of Outcomes



Hospital Outpatient Care

Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime